“Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.”, Blood, vol. 116, no. 24, pp. 5111-8, 2010.
, “Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl”, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
, “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
, “Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.”, J Infect Dis, vol. 207, no. 12, pp. 1888-97, 2013.
, “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
, “Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.”, J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
, “Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.”, J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.
,